The first participant has been treated in a Phase 1 clinical trial testing the CAR T-cell therapy CC-97540 (BMS-986353) in people with severe systemic lupus erythematosus (SLE). “The opportunity to provide lupus patients with access to this treatment, all while ensuring they receive the highest level of care, is…
The antimalarial agent hydroxychloroquine doesn’t appear to lower the risk of preeclampsia during pregnancy in women with lupus, a study reports. The study, “Hydroxychloroquine in lupus pregnancy and risk of preeclampsia,” was published in Arthritis & Rheumatology. Preeclampsia is a pregnancy complication marked by high…
Scientists have created small molecules that can block the activity of SLC15A4, an inflammatory protein — long considered undruggable — that’s known to play a central role in driving lupus and other autoimmune diseases. Further, the team showed that these molecules could reduce inflammation in lupus patient cells and…
Men with systemic lupus erythematosus (SLE) are more likely to experience kidney failure and heart attacks, while women with SLE are at higher risk of other symptoms, such as skin problems and arthritis, according to a new study. “Generally, our study suggests that men have the same spectrum of…
The U.S. Food and Drug Administration (FDA) has cleared Century Therapeutics to start a Phase 1 clinical trial that will test its off-the-shelf cell therapy CNTY-101 in people with systemic lupus erythematosus (SLE). The Phase 1 study will enroll people with moderate to severe SLE who’ve failed to respond…
The U.S. Food and Drug Administration (FDA) has given Gracell Biotechnologies the green light to start a Phase 1/2 clinical trial to test its experimental cell therapy GC012F in people with difficult-to-treat systemic lupus erythematosus (SLE). The study’s Phase 1 portion should start in 2024 to assess the safety,…
Depression and anxiety are more likely in people with systemic lupus erythematosus (SLE) who also are at a greater risk of heart disease, like those with obesity or high blood pressure, a study reports. “The findings of this study suggest the need for more intensive and global care, particularly…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to IMPT-514, a CAR T-cell therapy being developed by Immpact Bio for people with active, treatment-resistant lupus nephritis and systemic lupus erythematosus (SLE). Lupus nephritis is a serious complication of lupus characterized by kidney inflammation.
In both the U.S. and Europe, clinicians want to limit treatment with glucocorticoids — steroid hormones whose long-term use for autoimmune diseases is tied to serious side effects — among people with moderate to severe lupus. To that end, healthcare professionals are increasingly prescribing biological therapies like Benlysta…
Galapagos officially has launched a Phase 2 clinical trial that will test its oral therapy GLPG3667 — designed to ease disease severity in people with systemic lupus erythematosus (SLE) — at a half dozen sites in the U.S. The first participant has been randomized, or assigned to a treatment…
